StreetAlpha.app
Home › Stocks › BMY

Bristol Myers Squibb Co (BMY)

Healthcare
$58.80
▲ +0.79%
LAST CLOSE · NOV 20

Bristol Myers Squibb is a pharmaceutical company that develops and sells branded prescription medicines. It last closed at $58.80 on Nov 20, up 0.79% on the day. The next earnings report for BMY is expected around Thu, Feb 4, 2027. For the quarter ended Sep 2026, BMY reported EPS of $1.05 on revenue of $13.07B, with revenue up 6.9% from a year ago. Over its last 8 reports the stock moved an average of 3.7% the session after earnings. Over the last 12 months BMY insiders bought $0 of stock on the open market and sold $2.5M, according to SEC Form 4 filings.

AI Auto Pilots
Is BMY in one of our AI portfolios?
Five AI traders run real portfolios in the open, with every decision logged. Create a free account to see if they hold BMY.

Key Stats

Last 12 months
Results
Revenue
$50.0B
+4.2% vs a year ago
Net income
$9.2B
+53.1% vs a year ago
EPS (diluted)
$4.51
+51.9% vs a year ago
Free cash flow
$9.3B
18.6% margin
Valuation
Market cap
$120B
2.04B shares
P/E
13.0
Price over 12 month EPS
Price to sales
2.4
Market cap over revenue
Dividend yield
4.29%
$2.52 a share over 12 months
Balance sheet
Cash & equivalents
$9.6B
At Sep 30
Debt
$42.6B
At Sep 30
Shareholder equity
$23.4B
Shares outstanding
2.04B
At Oct 21
CEOGiovanni Caforio
Fiscal year endsDecember
ExchangeNYSE
Financials history
FY2021: $46.4B$46.4BFY2021FY2022: $46.2B$46.2BFY2022FY2023: $45.0B$45.0BFY2023FY2024: $48.3B$48.3BFY2024FY2025: $48.2B$48.2BFY2025

From BMY's SEC filings, latest 10-Q for the period ending Sep 30, 2026 (filed Oct 29). Last 12 months adds up the four latest quarters.

Next report
Feb 4
Estimated date · Time not announced
Reported EPS
$1.05
Quarter ended Sep 2026
Year ago EPS
$1.08
−2.8% on a GAAP basis
Revenue
$13.07B
+6.9% vs a year ago
Estimates and implied move
Consensus forecasts and the move options price in
EPS by quarter (GAAP)
Dec 2024: $0.04Dec '24Mar 2025: $1.20Mar '25Jun 2025: $0.64Jun '25Sep 2025: $1.08Sep '25Dec 2025: $0.53Dec '25Mar 2026: $1.31Mar '26Jun 2026: $1.62Jun '26Sep 2026: $1.05Sep '26Latest $1.05
Revenue by quarter
Dec 2024: $12.34BDec '24Mar 2025: $11.20BMar '25Jun 2025: $12.27BJun '25Sep 2025: $12.22BSep '25Dec 2025: $12.50BDec '25Mar 2026: $11.49BMar '26Jun 2026: $12.97BJun '26Sep 2026: $13.07BSep '26Latest $13.07B
How BMY moved after its last 8 reports
Average move the session after a report ±3.7%
Oct 29, 2026Time not announced+1.4%
Jul 30, 2026Time not announced+2.8%
Apr 30, 2026Time not announced+5.2%
Feb 5, 2026Time not announced+3.3%
Oct 30, 2025Time not announced+7.1%
Jul 31, 2025Time not announced−5.8%
Apr 24, 2025Time not announced+0.3%
Feb 6, 2025Time not announced−3.8%
Close to close, the session after each report, adjusted for splits. Past moves are no guide to the next one.
StreetAlpha's call on BMYStart your 7 day free trial to see StreetAlpha's call before the report, with the options flow, dark pool, history and technical scores behind it.Sign up freeSign in

Analyst Ratings & Price Targets

Analyst Ratings →
AI Starter and AI Pro
Full analyst coverage on BMY
  • Every upgrade, downgrade and initiation as it happens
  • Every price target change, raised or cut
  • Consensus rating with the average, high and low targets
  • Each firm's full rating history on BMY

Technical Analysis

BMY · as of the Nov 20 close · updated each morning
Turning down

The stock is 5% below its 20 day and 5% below its 50 day average. It is 3% below its 200 day average, so the longer trend is down. Momentum is weak (RSI 39). The nearest support is the Pivot S1 at $58.39, and the nearest resistance the swing high (Jun 30) at $58.88.

Short trendBearish
Long trendNeutral
MomentumWeak
StretchNormal
VolatilityHigh, 3.0%/day
Key levels
$68.6452 week high+16.7%
$62.44100 day average+6.2%
$61.8220 day average+5.1%
$61.4550 day average+4.5%
$60.43200 day average+2.8%
$59.51Pivot R1+1.2%
$59.10Pivot+0.5%
$58.88Swing high (Jun 30)+0.1%
$58.80Last close
$58.39Pivot S1−0.7%
$58.33Swing low (Oct 5)−0.8%
$45.2752 week low−23.0%
Indicators
RSI (14)39.45Weak, oversold below 30Neutral
MACD-0.43Below its signal lineBearish
Stochastic6.5Near the bottom of its rangeOversold
ADX (14)14.6No clear trend
Williams %R-88.0Oversold below −80, overbought above −20Oversold
CCI (20)-163.5Oversold below −100, overbought above 100Oversold
Rate of change−5.4%Change over 10 sessionsBearish
ATR (14)$1.79Typical daily range, 3.0% of price
MA 10Below
MA 20Below
MA 50Below
MA 100Below
MA 200Below
What happened before, for BMY

What happened before

See how BMY did after each of today's signals in the past: how often it was higher 10 sessions later, and the typical move, next to its usual record. Free with an account.

November seasonalityHow BMY usually does this month. See Seasonality

Calculated from daily prices after each close. Signals describe the chart, not where the stock will go. Past patterns often fail. Not investment advice.

AI Day Trader
Watch Claude day trade the open, live.
Every session it trades SPY, QQQ, IWM and two daily stock picks, with each call logged before the move.

Seasonality

How BMY has done in each calendar month: the average and median return, how often each month finished higher, and every year since 2005.

Loading…

See the stocks that usually rise in November →

Whale Options Flow

90D
Whale options flow for BMYHow many large options trades hit BMY, the bullish and bearish split, and every trade with strike, premium and expiry are shown to AI Starter and AI Pro members.Sign up freeSign in

See today’s whale options flow across the market →

Dark Pool

30D
Prints
Notional
Largest print
Loading…

BMY Institutional Ownership

Full report →
Fund sentiment · Q3 2026
Neutral
Strongly bearishNeutralStrongly bullish
  • ●1,187 buying vs 1,088 selling
  • ▼Held by funds -1.6 pts
  • ▲Funds holding +39
  • ▲Superinvestors: 3 added, 1 cut
  • ●Put/call 0.94 to 0.95
Q4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26Q2 '26Q3 '26
Funds holdingHeld by funds %
Q3 2026This quarterLast quarterChange
Funds holding2,5712,532+1.5%
In funds' top 102021−4.8%
Held by funds80.2%81.9%−1.6 pts
New / increased199 / 988145 / 975+6.0%
Reduced / sold out954 / 134986 / 160−5.1%
Put/call ratio0.950.94+0.8%
Top holders, biggest buyers and sellers, 8 quarters of charts and this season's filings so far.See BMY institutional ownership →

From SEC Form 13F filings for Sep 30, 2026. What the filings show, not a forecast: positions can be up to 45 days old and leave out short sales.

BMY Insider Trading

All filings →
Insider trading · 12 months
Insiders are only selling
Bought$00 buys · 0 insiders
Sold$2.5M4 sales · 4 insiders
2026-04 sold $1.9M2026-08 sold $34K2026-09 sold $403K2026-11 sold $241KDecMarJunSep
BoughtSoldlast 12 months
Trade dateInsiderTypeSharesPriceValue
Nov 5Julia A HallerDirectorSale3,800$63.31$241K
Sep 9Cristian MassacesiEVP,Chief Med Offr,Head of DevSale6,249$64.57$403K
Aug 25Phil M HolzerSVP and ControllerSale500$67.50$34K
Apr 1David V ElkinsEvp, CFOSale30,000$61.67$1.9M
Sep 2, 2025David V ElkinsEvp, CFOSale56,000$47.33$2.7M
Aug 2, 2025Bartie Wendy ShortEVP, Corporate AffairsSale378$44.23$17K
Every insider buy and sale for BMY over 2 years, with a link to each SEC filing. AI Pro members can get an alert the moment an insider trades.See BMY insider trades →

From SEC Form 4 filings by BMY's officers, directors and 10% owners. Open market buys and sales only; option exercises, gifts, awards and tax withholding are left out. Not investment advice.

BMY Stock Buybacks

See all S&P 500 buybacks →
Spent, 12 months
—
 
Left in program
$5.0B
4.2% of value
Shares outstanding, 12 months
+0.4%
More shares
Last quarter
$6.7M
Sep 2026
Avg price paid, last quarter
$63.42
105K shares bought
S&P 500 rank by spending
—
 
Spent each quarter, last 3 yearsTop bar $160.9M
Dec 2023: $5.7M, average price $54.87Mar 2024: $129.7M, average price $53.67Jun 2024: $10.3M, average price $48.59Sep 2024: $3.9M, average price $47.24Dec 2024: $7.4M, average price $54.70Mar 2025: $160.9M, average price $62.84Jun 2025: $11.5M, average price $52.79Sep 2025: $4.6M, average price $46.06Dec 2025: $8.4M, average price $47.46Mar 2026: $150.3M, average price $60.02Jun 2026: $11.1M, average price $57.03Sep 2026: $6.7M, average price $63.42
Dec 2023Sep 2026
For membersMonth by month buying, shares and the average price paid each month are shown to AI Starter and AI Pro members.

From the company's 10-Q filed Oct 29, 2026. Quarters are the company's own fiscal quarters. Yield and % of value use the latest close. Buybacks are not a forecast: in our testing, the biggest buyers did about the same as the average S&P 500 stock.

AI Auto Pilots

Paper trading

StreetAlpha runs autonomous AI traders powered by Anthropic's Claude. Each one reads options flow, dark pool prints, insider filings, sentiment, macro signals and technicals, then makes its own trading decisions in a paper portfolio. Every decision is logged and every trade is tracked, so you can see whether BMY is in one of them and how their past BMY trades turned out.

BMY in the AI portfolios
Loading…

BMY News Tone and Price

Loading…

Macro & Market News

All StreetAlpha news →

StreetAlpha hasn't covered BMY in an article yet. Here's the latest on the wider market.

BMY in the news

BMY Congress Trades

All congress trades →
Trades, 12 months
10
Buys
5
50%
Sells
5
50%
People
6
Last filed Nov 5
Who traded BMY · since 2014
Latest 5 filings of 147
$1K – $15KTraded Oct 13, 2026Filed Nov 5, 2026
$1K – $15KTraded Oct 7, 2026Filed Nov 5, 2026
$1K – $15KTraded Mar 27, 2026Filed Jul 21, 2026
$15K – $50KTraded May 7, 2026Filed Jun 11, 2026
$1K – $15KTraded Dec 18, 2025Filed Jan 15, 2026
PersonTypeAmountTradedFiledDelay
Ro KhannaD · CABuy$1K – $15KOct 13, 2026Nov 5, 202623 d
Ro KhannaD · CASell$1K – $15KOct 7, 2026Nov 5, 202629 d
Alan ArmstrongR · OKBuy$1K – $15KMar 27, 2026Jul 21, 2026116 d
Mike KellyR · PASell$15K – $50KMay 7, 2026Jun 11, 202635 d
Julie JohnsonD · TXSell$1K – $15KDec 18, 2025Jan 15, 202628 d

From official House and Senate disclosure reports, filed up to 45 days after the trade and shown in dollar ranges. Not investment advice. Use limited by 5 U.S.C. 13107. About this data

About Bristol Myers Squibb

Bristol Myers Squibb is a pharmaceutical company based in Princeton, New Jersey. It develops, produces and sells branded prescription medicines, including Eliquis, Opdivo and Orencia, and it continues to research new drugs. Its products are paid for through government programs and commercial insurance plans, so pricing and coverage rules affect its sales.

Headquarters
Princeton, NJ
Founded
1989